Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2005-004984-43-IT
EUCTR2005-004984-43-IT
Active, not recruiting
Not Applicable

Randomized, double-blind, placebo controlled trial on the efficacy of montelukast in exercise-induced asthma in children - MONTEIA

IVERSITA DEGLI STUDI DI UDINE0 sites22 target enrollmentJanuary 9, 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsSINGULAIR BB 28 CPR MAST.5MG

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
IVERSITA DEGLI STUDI DI UDINE
Enrollment
22
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 9, 2006
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
IVERSITA DEGLI STUDI DI UDINE

Eligibility Criteria

Inclusion Criteria

  • •outpatients aged 6 to 14 years with a history of typical symptoms of exercise\-induced asthma. pre\-exercise FEV1 at least 75 of the predicted value 15 or greater decrease in FEV1 after a standardized treadmill exercise challenge Absence of farmacological treatment
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) no
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •Sensitivity to montelukast Singulair or its components. a pulmonary disease other than asthma or other cronic pathologies acute upper respiratory tract infection

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Study to assess the effectiveness of high doses of immunoglobulin in the treatment of polyneuropathy painful diabetic resistant to conventional therapiespainful diabetic polyneuropathy resistant to conventional therapiesMedDRA version: 14.1Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2010-023883-42-ITAZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)
Active, not recruiting
Phase 1
Randomized, double-blind, placebo-controlled trial to determine the capacity of VAK694 to elicit long term immune tolerance when combined with subcutaneous allergen immunotherapy for the treatment of seasonal allergic rhinitis
EUCTR2009-013429-40-GBovartis Pharma Services AG
Active, not recruiting
Phase 1
Study of RV521 for the treatment of adults who have received a blood cell transplant and that have a respiratory infection caused by the virus RSV
EUCTR2019-003746-33-FRReViral Ltd.200
Recruiting
Phase 3
Efficacy of Aripiprazole adjunctive treatment on body weight, metabolic parameters, clinical efficacy, and adverse events in people with psychotic disorders on treatment with Clozapine â?? A randomized, double-blind, placebo-controlled trialHealth Condition 1: null- SchizophreniaSchizoaffective disorderAntipsychotic induced weight gainMetabolic syndrome
CTRI/2013/02/003397Christian Medical College60
Active, not recruiting
Phase 1
Randomized, double-blind, placebo-controlled trial to compare the effect, three months of follow-on pulse pressure and vascular function of isosorbide mononitrate extended release, associated with antihypertensive treatment in patients over 65 years refractory isolated systolic hypertension.Refractory isolated systolic hypertensionTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2012-002988-10-ESFundación para la investigacion Biomedica